SL BIO Ltd. has finalized its merger with Horizon Space Acquisition II and will begin trading on Nasdaq under the ticker SLBT. The deal, valuing SL BIO at about $5.57 billion and including $7.8 million in PIPE financing, provides capital to develop its proprietary Gamma delta T cell therapies targeting solid tumors like pancreatic and brain cancers. This public listing enhances SL BIO's access to U.S. capital markets, supporting clinical growth, potential acquisitions, and global partnerships. The company also strengthened its leadership and board to guide its next phase as a Nasdaq-listed entity focused on scalable, standardized cell therapy solutions for oncology.
The Carlyle Group has acquired South Korea's Chung Ho Group, a home and healthcare appliance rental platform, for $700 million, driven by inheritance tax issues and lack of heirs. Meanwhile, GoHealth, a digital health and Medicare insurance marketpla...
Abbott's board announced a quarterly dividend of 63 cents per share, marking the company's 410th consecutive quarterly dividend since 1924. This consistent dividend payment underscores Abbott's long-standing commitment to returning value to sharehold...
A fire destroyed Medline's 1 million-square-foot medical equipment warehouse in Tracy, California, affecting about 4% of its U.S. warehouse space. The blaze caused inventory losses and disrupted operations, creating short-term margin pressure as the ...
SpaceX is choosing to focus on long-term growth rather than immediate profitability, similar to Amazon's approach in its early years. Experts say SpaceX could be profitable now if it reduced spending on projects like Starship and AI infrastructure, b...
Cornerstone has released an updated version of the EPA's GHG Emission Factors Hub, providing free, consolidated data for scopes 1, 2, and 3 greenhouse gas emissions. This update includes new factors for air travel, refrigerants, and aligns with the l...
